Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SND-584
- Development stage
- Preclinical
- Lead developer
- Pelago Bioscience
- Modality
- Small Molecules
01
Overview
SND-584 is a preclinical-stage small molecule drug candidate being developed by Pelago Bioscience AB. While specific details regarding its biological target and mechanism of action remain proprietary, the program is reportedly focused on a broad range of therapeutic areas, including oncology (neoplasms), metabolic and endocrine disorders, as well as diseases of the immune and lymphatic systems. Pelago Bioscience typically utilizes its proprietary Cellular Thermal Shift Assay (CETSA) technology to identify and validate drug-target interactions, suggesting SND-584 may have been identified or optimized using this platform to ensure robust target engagement in a cellular environment.
Beyond the preview
Go deeper on SND-584.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SND-584.